COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Bioresource Technology's state of the art manufacturing facility in Weston, Florida
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Many kids who have heart transplants live a normal, healthy life once they recover from surgery.
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Amarex Clinical Research guides its client to phase II of FDA trials
New Director supports NASDAQ rule on diversity
Subscribe To Our Newsletter & Stay Updated
